Cytokinetics (CYTK) SG&A Expense (TTM): 301.02M | YCharts

Cytokinetics, Inc. (CYTK)

55.55 -8.05 (-12.66%) USD | NASDAQ | Nov 05, 16:00

56.48 +0.93 (+1.67%) After-Hours: 06:01

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2004. Start Trial.

Date	Value
September 30, 2026	301.02M
June 30, 2026	370.47M
March 31, 2026	331.80M
December 31, 2025	284.27M
September 30, 2025	254.89M
June 30, 2025	242.08M
March 31, 2025	227.18M
December 31, 2024	215.31M
September 30, 2024	197.09M
June 30, 2024	180.55M
March 31, 2024	169.45M
December 31, 2023	173.61M
September 30, 2023	183.47M
June 30, 2023	191.58M
March 31, 2023	194.57M
December 31, 2022	177.98M
September 30, 2022	157.81M
June 30, 2022	135.79M
March 31, 2022	114.28M
December 31, 2021	96.80M
September 30, 2021	76.90M
June 30, 2021	63.00M
March 31, 2021	55.97M
December 31, 2020	52.82M
September 30, 2020	49.50M

Date	Value
June 30, 2020	46.95M
March 31, 2020	42.62M
December 31, 2019	39.61M
September 30, 2019	36.58M
June 30, 2019	34.00M
March 31, 2019	32.20M
December 31, 2018	32.03M
September 30, 2018	34.73M
June 30, 2018	37.23M
March 31, 2018	37.62M
December 31, 2017	36.47M
September 30, 2017	32.88M
June 30, 2017	30.44M
March 31, 2017	29.10M
December 31, 2016	27.82M
September 30, 2016	26.68M
June 30, 2016	24.74M
March 31, 2016	22.14M
December 31, 2015	19.67M
September 30, 2015	18.70M
June 30, 2015	17.41M
March 31, 2015	17.38M
December 31, 2014	17.27M
September 30, 2014	16.80M
June 30, 2014	16.44M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years

Start Trial

--

Minimum

--

Maximum

--

Average

--

Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks

Start Trial

Bristol Myers Squibb Co.	7.323B
BridgeBio Pharma, Inc.	709.10M
Alnylam Pharmaceuticals, Inc.	1.338B
BioMarin Pharmaceutical, Inc.	1.100B
Exelixis, Inc.	564.82M